Drug Price Regulation
Drug prices are regulated in a legal framework that organizes the negotiation between pharmaceutical firms and a third-party payer responsible for healthcare reimbursement. This regulation aims at compensating for market failures associated with drug specificities. Explicit economic reasoning through the so-called health technology assessment framework is increasingly embedded in the institutional and administrative process of the evaluation procedure leading to market access, pricing and reimbursement for new drugs.
- Arrow K (1963) Uncertainty and the welfare economics of medical care. Am Econ Rev 53:941–973Google Scholar
- Drummond M, Sculpher M, Claxton K, Stoddart G , Torrance G (2015) Methods for the economic evaluation of health care programmes. Oxford University Press, New YorkGoogle Scholar
- Hurley J (2000) An overview of the normative economics of the health sector. In: Culyer A, Newhouse J (eds) Handbook of health economics. Elsevier, Amsterdam, pp 55–118Google Scholar
- Morris S, Devlin N, Parkin D (2007) Economic analysis in health care. Wiley, New YorkGoogle Scholar
- Rice T, Rosenau P, Unruh L, Barnes A, Saltman R, van Ginneken E (2013) United States of America: health system review. Health Syst Transit 15:70–80Google Scholar